Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis
Tóm tắt
Digital vascular complications are a major cause of disease-related morbidity in systemic sclerosis (SSc). Demonstrating treatment efficacy in the management of cutaneous vascular manifestations of SSc has been challenging. The contrasting findings of clinical trials of Raynaud’s phenomenon (RP) and digital ulcers (DU) for within-class medications have led to doubt on likely efficacy; with geographic variation in reimbursement policies and variation in clinical practice. In this paper, we compare the contrasting trials of phosphodiesterase inhibitors in the management of SSc-RP and endothelin receptor antagonists in the management of SSc-DU to help identify potential barriers for future successful clinical trials in these fields. Scrutiny of the contrasting clinical trials in these fields has identified a number of important differences in trial design and patient characteristics that may account for differences in clinical trial outcomes. These factors include differences in patient selection, impact of seasonal variation in weather, and the definitions applied to SSc manifestations. The contrasting findings of clinical trials of within-class medications for the management of digital vascular manifestations of SSc have been disappointing but can provide investigators with valuable insight into treatment response in SSc and the pre-requisites for future effective clinical trial design.
Tài liệu tham khảo
Hughes M, Pauling JD. Exploring the patient experience of digital ulcers in systemic sclerosis. Semin Arthritis Rheum. 2018. https://doi.org/10.1016/j.semarthrit.2018.08.001.
Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D. The patient experience of Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford). 2018;58:18–26. https://doi.org/10.1093/rheumatology/key026.
Pauling JD. The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. Expert Rev Clin Immunol. 2018;14(5):431–42. https://doi.org/10.1080/1744666x.2018.1464390.
• Fernandez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm G. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheum. 2018;70(11):1820–8. https://doi.org/10.1002/art.40560 This work highlights uncertainty amongst SSc experts regarding the positioning of treatments for digital vasculopathy in SSc.
•• Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res. 2013;65(9):1460–71. https://doi.org/10.1002/acr.22018 This valuable meta-analysis provides a summary of the treatment efficacy of different classes of vasodilator therapy for the management of SSc-DU.
•• Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696–9. https://doi.org/10.1136/annrheumdis-2012-202836 This valuable meta-analysis provides a summary of the treatment efficacy of different classes of vasodilator therapy for the management of SSc-RP.
Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016;55(10):1906–10. https://doi.org/10.1093/rheumatology/kew224.
Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud’s condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010;69(3):588–91. https://doi.org/10.1136/ard.2009.107706.
Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology. 2010;49(12):2420–8.
Agarwal V, Ghosh P, Sharma A, Bhakuni D, Kumar S, Singh U, et al. Efficacy of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study. Arthritis Rheum. 2010;62(Suppl 10):S872.
Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, et al. Randomized placebo-controlled crossover trial of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36(10):2264–8.
Impens AJ, Rothman J, Schiopu E, Cole JC, Dang J, Gendrano N, et al. Sexual activity and functioning in female scleroderma patients. Clin Exp Rheumatol. 2009;27(3 Suppl 54):38–43.
Impens AJ, Seibold JR. Vascular alterations and sexual function in systemic sclerosis. Int J Rheumatol. 2010;2010:139020–5. https://doi.org/10.1155/2010/139020.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581–90.
Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41(4):670–7. https://doi.org/10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I.
Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis. 2008;67(5):703–9. https://doi.org/10.1136/ard.2007.078923.
Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum. 2002;46(9):2410–20. https://doi.org/10.1002/art.10486.
Pauling JD, Reilly E, Smith T, Frech T. Evolving symptoms of Raynaud’s phenomenon in systemic sclerosis are associated with physician and patient-reported assessments of disease severity. Arthritis Care Res. 2018;In press.
Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, et al. Multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis. Arthritis Care Res. 2018;70(9):1373–84. https://doi.org/10.1002/acr.23475.
Administration. NOaA. NowData – NOAA Online Weather Data”. Accessed from Wikipedia. https://en.wikipedia.org/wiki/Ann_Arbor,_Michigan#Climate. Accessed 17 Jan 2019.
Pauling JD, Reilly E, Smith T, Frech T. Factors influencing Raynaud’s condition score diary outcomes in systemic sclerosis. J Rheumatol. 2018;In Press.
Morgan ND, Shah AA, Mayes MD, Domsic RT, Medsger TA Jr, Steen VD, et al. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore). 2017;96(51):e8980. https://doi.org/10.1097/MD.0000000000008980.
Hrobjartsson A, Forfang E, Haahr MT, Als-Nielsen B, Brorson S. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol. 2007;36(3):654–63. https://doi.org/10.1093/ije/dyn020.
Department IM. Lucknow Climate and Temperature. http://www.imd.gov.in/section/climate/extreme/lucknow2.htm. Accessed 17 Jan 2019
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39. https://doi.org/10.1136/annrheumdis-2016-209909.
Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Ingegnoli F, et al. Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: a SCTC vascular working group report. J Scleroderma Relat Disord. 2018;3(3):249–52. https://doi.org/10.1177/2397198318774307.
Pauling JD, Saketkoo LA, Domsic RT. Patient perceptions of the Raynaud’s Condition Score diary provide insight into its performance in clinical trials of Raynaud’s phenomenon. Arthritis Rheumatol. 2018. https://doi.org/10.1002/art.40481.
Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton CP, et al. An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. J Scleroderma Relat. 2018; In Press.
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985–93. https://doi.org/10.1002/art.20676.
Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32–8. https://doi.org/10.1136/ard.2010.130658.
Patel T, McKeage K. Macitentan: first global approval. Drugs. 2014;74(1):127–33. https://doi.org/10.1007/s40265-013-0156-6.
Giner SE. Swift and complete healing of digital ulcers after macitentan treatment. Case Rep Rheumatol. 2016;2016:1718309–4. https://doi.org/10.1155/2016/1718309.
Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA. 2016;315(18):1975–88. https://doi.org/10.1001/jama.2016.5258.
Hughes M, Bhushan M, Chakravarty K, Denton CP, Dubey S, Guiducci S, et al. A study examining the reliability of digital ulcer definitions as proposed by the Uk Scleroderma study group: challenges and insights for future clinical trial design. Rheumatology. 2018;57.
Baron M, Chung L, Gyger G, Hummers L, Khanna D, Mayes MD, et al. Consensus opinion of a north American working group regarding the classification of digital ulcers in systemic sclerosis. Clin Rheumatol. 2014;33(2):207–14. https://doi.org/10.1007/s10067-013-2460-7.
Herrick AL, Roberts C, Tracey A, Silman A, Anderson M, Goodfield M, et al. Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum. 2009;60(3):878–82. https://doi.org/10.1002/art.24333.
•• Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol. 2007;34(12):2423–30 This paper proposes the presence of different types of SSc-DU that could have important implications for SSc-DU design.
Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii19–24. https://doi.org/10.1093/rheumatology/kep105.
Caramaschi P, Martinelli N, Volpe A, Pieropan S, Tinazzi I, Patuzzo G, et al. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol. 2009;28(7):807–13. https://doi.org/10.1007/s10067-009-1155-6.
Hughes M, Murray A, Denton CP, Herrick AL. Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy? Med Hypotheses. 2018;116:101–4. https://doi.org/10.1016/j.mehy.2018.04.024.
Pauling JD. Vasodilation is not the only approach to the management of cutaneous ulceration in systemic sclerosis. Rheumatology (Oxford). 2017;56(9):1559. https://doi.org/10.1093/rheumatology/kex175.
Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2016;75(6):1009–15. https://doi.org/10.1136/annrheumdis-2014-207001.
Suliman YA, Bruni C, Johnson SR, Praino E, Alemam M, Borazan N, et al. Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition. J Scleroderma Relat Disord. 2017;2(2):115–20. https://doi.org/10.5301/jsrd.5000236.
Li W, Frech TM. The critical need for accurately defining digital ulcers in scleroderma. J Scleroderma Relat. 2017;2(2):69–71. https://doi.org/10.5301/jsrd.5000238.
Khanna D, Poiraudeau S, Gelhorn H, Hunsche E, Papadakis K, Perchenet L, et al. Development and content validity of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU) Scale. Arthritis Rheum. 2011;63(10):S726-S.
Bruni C, Ngcozana T, Braschi F, Pucci T, Piemonte G, Benelli L, et al. Preliminary validation of the digital ulcer clinical assessment score in systemic sclerosis. J Rheumatol. 2018. https://doi.org/10.3899/jrheum.171486.